Compare Revvity Inc (RVTY) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Workiva Inc — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while Workiva Inc trades at $73.25 (market cap $4.01B). The key difference: Revvity Inc is far larger — about 4.2× Workiva Inc's market cap, and Revvity Inc pays a 0.18% dividend while Workiva Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Workiva Inc for 21 Days on average.
| RVTY | WK | |
|---|---|---|
Market Cap | $16.98B | $4.01B |
Volume | 1,456,900 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $157.36 | $93.31 |
52-Week Low | $82.26 | $44.31 |
Typical Hold Time | 12 Days | 21 Days |
Enterprise Value | $19.30B | $3.99B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Workiva (WK) trades at $73.69, up 3.02% with strong technical momentum and bullish moving averages. The company shows impressive revenue growth with 2026 revenue reaching $966 million and net income turning positive at $47 million. Recent earnings beats and AI product innovations at Amplify 2026 conference highlight operational strength. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and an $86 consensus price target.
WK presents a compelling growth story with improving profitability and strong analyst support, though elevated valuation multiples and technical overbought conditions warrant caution. The stock's 88.89% buy rating and 16.7% upside to consensus target suggest continued optimism, but investors should monitor execution of AI initiatives and competitive pressures in the regulatory technology space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
